The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Voxelotor is a new drug for adolescents and adults with sickle cell disease that improves
hemoglobin levels and reduces the incidence of worsening anemia. However, it is unclear
whether this increase in hemoglobin is associated with a reduction in cerebral metabolic
stress. This study will measure the effects of voxelotor on cerebral hemodynamics.